TrialMenopause (New York, N.Y.)2018

Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.

Michael R McClung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.